Wearable Heart Sensor May Replace Treadmill Tests for Measuring Fitness Age
A completed trial tested whether seismocardiography can accurately estimate VO2max and biological age without exhaustive exercise testing.
Summary
Researchers at the University of Copenhagen completed a clinical trial validating a new, non-exercise method for estimating cardiorespiratory fitness using seismocardiography, a technique that detects subtle vibrations from the beating heart via a chest-worn accelerometer. Rather than pushing patients to exhaustion on a treadmill, this approach uses resting cardiac signals to predict VO2max, a powerful marker of cardiovascular health and longevity. The trial also assessed a biological age model, which estimates functional health status independent of chronological age. Both validity and test-retest reliability were evaluated. If proven accurate and reliable, this method could democratize fitness assessment, enabling routine VO2max screening in clinical offices, remote health programs, and underserved settings where expensive laboratory equipment is unavailable.
Detailed Summary
Cardiorespiratory fitness, measured as VO2max, is one of the strongest predictors of cardiovascular disease risk and all-cause mortality. Yet the gold-standard measurement demands maximal exertion and costly metabolic lab equipment, putting it out of reach for most clinical settings. Finding a simpler, reliable alternative could transform how clinicians assess and monitor patient health over time.
This completed clinical trial from the University of Copenhagen investigated the validity and reliability of a non-exercise VO2max prediction model incorporating seismocardiography. SCG records mechanical vibrations from cardiac contractions using an accelerometer placed on the chest wall. Because VO2max is primarily constrained by maximal cardiac output, SCG-derived cardiac performance metrics offer a physiologically grounded basis for fitness estimation without requiring exhaustive exercise.
The trial had two primary objectives: first, to validate the SCG-based VO2max prediction model against established reference methods and assess its test-retest reliability; second, to evaluate the reliability of a biological age model designed for health promotion interventions. Biological age attempts to quantify functional metabolic status and disease vulnerability independently of chronological age, offering a more nuanced picture of an individual's health trajectory.
Full results have not been published in the available abstract, so specific accuracy metrics, correlation coefficients, and reliability indices cannot be reported here. The study design, however, reflects rigorous scientific standards, addressing gaps identified in earlier cross-sectional validation work by adding a reliability component essential for clinical adoption.
If validated, this technology could enable routine VO2max monitoring in primary care, telemedicine, and remote populations. Clinicians could track cardiorespiratory fitness trends over time, guide exercise prescriptions, and flag cardiovascular risk earlier. Integration of biological age scoring alongside VO2max could further enrich preventive health assessments, making this a potentially high-impact tool for longevity-focused medicine.
Key Findings
- SCG uses a chest accelerometer to estimate VO2max without requiring maximal exercise or expensive lab equipment.
- The trial evaluated both validity and test-retest reliability, addressing key gaps from prior cross-sectional studies.
- A biological age model was also assessed for reliability as a complementary health promotion tool.
- VO2max is among the strongest known predictors of cardiovascular mortality and longevity outcomes.
- If reliable, this method could enable routine fitness screening in primary care and remote health settings.
Methodology
This is a completed clinical trial (NCT05356871) sponsored by the University of Copenhagen assessing the validity and reliability of an SCG-based VO2max prediction model. The study used a repeated-measures design to evaluate both criterion validity against a reference standard and test-retest reliability. Full protocol and results details are not available from the abstract alone.
Study Limitations
This summary is based on the abstract only, as the full trial results are not publicly available; no specific accuracy or reliability statistics can be reported. The prediction model's performance in diverse populations, age groups, and clinical subgroups remains unknown from available information. Publication of peer-reviewed results is needed before clinical adoption can be recommended.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.